Shamburg News · 8-K filed Oct 1, 2026, 8:00 AM EDT
Allarity Therapeutics Provides Update on DRP Technology, Patents and In-House Lab
ALLR · Allarity Therapeutics, Inc.
- Other event
- Materiality: low
Allarity Therapeutics announced an update on its Drug Response Predictor (DRP) technology, patent portfolio and in-house laboratory capabilities, which it said support clinical development of stenoparib and expand potential external partnership opportunities. The company cited recently awarded patents and CLIA certification of its in-house lab, which it said allow it to extend the test's use as a companion diagnostic and retain sole control of the clinical test. The update was furnished under Item 8.01 via a press release dated September 30, 2026.
Source: SEC EDGAR, Form 8-K, Items 8.01, 9.01, accession 0001213900-26-105457.
Written from the filing by Shamburg Markets. Figures are as reported by the company.